<p>Hims
&amp; Hers Health (NYSE:HIMS - 获取免费报告) 在周二发布给投资者的研究报告中，银行美林的股票分析师将其目标价格从 21.00 美元上调至 22.00 美元。该公司目前对该股票的评级为 “表现不佳”。银行美林的目标价格意味着该公司当前价格可能下跌 36.56%。</p>
<p>获取 <strong>Hims
&amp; Hers Health</strong> 的提醒：</p>
<ul>
<li>Viking Therapeutics 是下一个热门的 GLP-1 股票吗？</li>
</ul>
<p>其他一些股票研究分析师最近也对 HIMS 发布了报告。Truist Financial 将 Hims
&amp; Hers Health 的目标价格从 24.00 美元上调至 39.00 美元，并在 2 月 26 日的研究报告中给予该公司 “持有” 评级。Leerink Partners 将 Hims
&amp; Hers Health 的目标价格从 24.00 美元上调至 40.00 美元，并在 2 月 25 日的研究报告中给予该公司 “市场表现” 评级。Needham
&amp; Company LLC 将 Hims
&amp; Hers Health 的目标价格从 31.00 美元上调至 61.00 美元，并在 2 月 25 日的研究报告中给予该股票 “买入” 评级。花旗集团在 3 月 6 日的报告中重申了 “卖出” 评级，并对 Hims
&amp; Hers Health 的股票设定了 27.00 美元的目标价格。最后，Canaccord Genuity Group 将 Hims
&amp; Hers Health 的目标价格从 38.00 美元上调至 68.00 美元，并在 2 月 19 日的报告中给予该股票 “买入” 评级。两位股票研究分析师对该股票给予了卖出评级，七位给予了持有评级，六位给予了买入评级。根据 MarketBeat 的数据，该股票的共识评级为 “持有”，平均目标价格为 37.31 美元。</p>
<p>** 查看我们最新的 Hims
&amp; Hers Health 股票报告 **</p>
<h2>Hims</h2>
<p>&amp; Hers Health 股票上涨 4.6%</p>
<ul>
<li>尽管面临挑战，诺和诺德计划击败 GLP-1 竞争对手</li>
</ul>
<p>HIMS 周二开盘价为 34.68 美元。该公司的 50 日移动平均价格为 38.64 美元，200 日移动平均价格为 28.37 美元。Hims
&amp; Hers Health 的 52 周低点为 11.20 美元，52 周高点为 72.98 美元。该公司的市值为 77 亿美元，市盈率为 78.82，贝塔值为 1.37。</p>
<p>Hims
&amp; Hers Health (NYSE:HIMS - 获取免费报告) 最近在 2 月 24 日发布了季度财报。该公司报告每股收益（EPS）为 0.11 美元，超出分析师共识预期的 0.09 美元，超出幅度为 0.02 美元。Hims
&amp; Hers Health 的净利润率为 8.19%，股本回报率为 10.97%。该公司本季度的收入为 4.8114 亿美元，而分析师预期为 4.9456 亿美元。整体来看，卖方分析师预计 Hims
&amp; Hers Health 本财年的每股收益将为 0.29 美元。</p>
<h2>Hims</h2>
<p>&amp; Hers Health 的内部交易</p>
<ul>
<li>MarketBeat 周回顾 – 03/03 - 03/07</li>
</ul>
<p>在相关消息中，内部人士 Soleil Boughton 于 1 月 6 日以交易方式出售了 268,932 股该股票。该股票的平均售价为 27.75 美元，总价值为 7,462,863.00 美元。出售完成后，该内部人士现在直接持有该公司 169,803 股，价值约为 4,712,033.25 美元。这代表其持股减少了 61.30%。该出售在提交给证券交易委员会的文件中披露，文件可通过 SEC 网站访问。此外，首席执行官 Andrew Dudum 于 1 月 16 日以交易方式出售了 36,460 股该公司的股票。该股票的平均售价为 27.09 美元，总价值为 987,701.40 美元。交易完成后，首席执行官现在持有该公司 27,918 股，价值约为 756,298.62 美元。这代表其持股减少了 56.63%。该出售的披露信息可以在此找到。内部人士在过去 90 天内出售了 890,592 股公司股票，价值 31,677,291 美元。公司内部人士持有该公司股票的 17.71%。</p>
<h2>Hims</h2>
<p>&amp; Hers Health 的机构交易</p>
<p>几家大型投资者最近购买和出售了 HIMS 的股票。Crewe Advisors LLC 在第四季度购买了 Hims
&amp; Hers Health 的新头寸，价值 28,000 美元。Raleigh Capital Management Inc. 在第四季度将其在 Hims
&amp; Hers Health 的持股增加了 1,100.0%。Raleigh Capital Management Inc. 现在拥有该公司 1,200 股股票，价值 29,000 美元，此前在上个季度又购买了 1,100 股。Blume Capital Management Inc. 在第四季度将其在 Hims
&amp; Hers Health 的持股增加了 100.0%。Blume Capital Management Inc. 现在拥有该公司 1,200 股股票，价值 29,000 美元，此前在上个季度又购买了 600 股。Smartleaf Asset Management LLC 在第四季度将其在 Hims
&amp; Hers Health 的持股增加了 4,415.6%。Smartleaf Asset Management LLC 现在拥有该公司 1,445 股股票，价值 36,000 美元，此前在上个季度又收购了 1,413 股。最后，Summit Securities Group LLC 在第四季度购买了 Hims
&amp; Hers Health 的新股份，价值约 38,000 美元。机构投资者和对冲基金持有该公司 63.52% 的股票。</p>
<h2>关于 Hims</h2>
<p>&amp; Hers Health</p>
<p>(获取免费报告)</p>
<p>Hims
&amp; Hers Health, Inc. 运营一个远程医疗咨询平台。它将消费者与医疗专业人员连接，使他们能够获得心理健康、性健康、皮肤病和初级护理的医疗服务。该公司成立于 2017 年，总部位于加利福尼亚州旧金山。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Hims
&amp; Hers Health</li>
<li>基础材料股票投资</li>
<li>Joby Aviation 股票：维珍大西洋交易信号巨大潜力</li>
<li>恒生指数是什么？</li>
<li>Kohl’s 发布了另一个 “厨房水槽” 季度，但新 CEO 有计划</li>
<li>有哪些值得购买的大型股票？</li>
<li>西南航空可能会从这里三倍增长——这是方法</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Hims &amp; Hers Health 吗？</h2>
<p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Hims &amp; Hers Health 并不在名单上。</p>
<p>虽然 Hims &amp; Hers Health 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HIMS

<p>美国银行将 Hims & Hers Health（纽约证券交易所代码：HIMS）的目标股价从 21.00 美元上调至 22.00 美元，维持 “表现不佳” 的评级。这个新目标暗示当前价格可能下跌 36.56%。其他分析师的观点各异，目标股价范围从 24.00 美元到 68.00 美元不等。Hims & Hers Health 的股票开盘价为 34.68 美元，市值为 77 亿美元，市盈率为 78.82。该公司报告上个季度每股收益为 0.11 美元，超出预期</p>

<p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) had its price target raised by stock analysts at Bank of America from $21.00 to $22.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an &#34;underperform&#34; rating on the stock. Bank of America's price target would indicate a potential downside of 36.56% from the company's current price.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health (NYSE:HIMS - 获取免费报告) 在周二发布给投资者的研究报告中，银行美林的股票分析师将其目标价格从 21.00 美元上调至 22.00 美元。该公司目前对该股票的评级为 “表现不佳”。银行美林的目标价格意味着该公司当前价格可能下跌 36.56%。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Hims
&amp; Hers Health</strong> 的提醒：</p>
</div><ul>
<li>Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics 是下一个热门的 GLP-1 股票吗？</li>
</ul>
</div><p>A number of other equities research analysts also recently issued reports on HIMS. Truist Financial lifted their price target on shares of Hims &amp; Hers Health from $24.00 to $39.00 and gave the company a &#34;hold&#34; rating in a research report on Wednesday, February 26th. Leerink Partners increased their price objective on Hims &amp; Hers Health from $24.00 to $40.00 and gave the company a &#34;market perform&#34; rating in a research note on Tuesday, February 25th. Needham &amp; Company LLC lifted their price objective on Hims &amp; Hers Health from $31.00 to $61.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday, February 25th. Citigroup restated a &#34;sell&#34; rating and issued a $27.00 target price on shares of Hims &amp; Hers Health in a report on Thursday, March 6th. Finally, Canaccord Genuity Group lifted their price target on shares of Hims &amp; Hers Health from $38.00 to $68.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, February 19th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of &#34;Hold&#34; and an average price target of $37.31.</p>
<div class="lb-trans"><p>其他一些股票研究分析师最近也对 HIMS 发布了报告。Truist Financial 将 Hims
&amp; Hers Health 的目标价格从 24.00 美元上调至 39.00 美元，并在 2 月 26 日的研究报告中给予该公司 “持有” 评级。Leerink Partners 将 Hims
&amp; Hers Health 的目标价格从 24.00 美元上调至 40.00 美元，并在 2 月 25 日的研究报告中给予该公司 “市场表现” 评级。Needham
&amp; Company LLC 将 Hims
&amp; Hers Health 的目标价格从 31.00 美元上调至 61.00 美元，并在 2 月 25 日的研究报告中给予该股票 “买入” 评级。花旗集团在 3 月 6 日的报告中重申了 “卖出” 评级，并对 Hims
&amp; Hers Health 的股票设定了 27.00 美元的目标价格。最后，Canaccord Genuity Group 将 Hims
&amp; Hers Health 的目标价格从 38.00 美元上调至 68.00 美元，并在 2 月 19 日的报告中给予该股票 “买入” 评级。两位股票研究分析师对该股票给予了卖出评级，七位给予了持有评级，六位给予了买入评级。根据 MarketBeat 的数据，该股票的共识评级为 “持有”，平均目标价格为 37.31 美元。</p>
</div><p><strong>View Our Latest Stock Report on Hims &amp; Hers Health</strong></p>
<div class="lb-trans"><p>** 查看我们最新的 Hims
&amp; Hers Health 股票报告 **</p>
</div><h2>Hims &amp; Hers Health Stock Up 4.6 %</h2>
<div class="lb-trans"><h2>Hims</h2>
<p>&amp; Hers Health 股票上涨 4.6%</p>
</div><ul>
<li>Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors</li>
</ul>
<div class="lb-trans"><ul>
<li>尽管面临挑战，诺和诺德计划击败 GLP-1 竞争对手</li>
</ul>
</div><p>HIMS opened at $34.68 on Tuesday. The business has a 50 day moving average price of $38.64 and a two-hundred day moving average price of $28.37. Hims &amp; Hers Health has a 52 week low of $11.20 and a 52 week high of $72.98. The company has a market cap of $7.70 billion, a PE ratio of 78.82 and a beta of 1.37.</p>
<div class="lb-trans"><p>HIMS 周二开盘价为 34.68 美元。该公司的 50 日移动平均价格为 38.64 美元，200 日移动平均价格为 28.37 美元。Hims
&amp; Hers Health 的 52 周低点为 11.20 美元，52 周高点为 72.98 美元。该公司的市值为 77 亿美元，市盈率为 78.82，贝塔值为 1.37。</p>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. Hims &amp; Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. As a group, sell-side analysts expect that Hims &amp; Hers Health will post 0.29 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health (NYSE:HIMS - 获取免费报告) 最近在 2 月 24 日发布了季度财报。该公司报告每股收益（EPS）为 0.11 美元，超出分析师共识预期的 0.09 美元，超出幅度为 0.02 美元。Hims
&amp; Hers Health 的净利润率为 8.19%，股本回报率为 10.97%。该公司本季度的收入为 4.8114 亿美元，而分析师预期为 4.9456 亿美元。整体来看，卖方分析师预计 Hims
&amp; Hers Health 本财年的每股收益将为 0.29 美元。</p>
</div><h2>Insider Transactions at Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>Hims</h2>
<p>&amp; Hers Health 的内部交易</p>
</div><ul>
<li>MarketBeat Week in Review – 03/03 - 03/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 03/03 - 03/07</li>
</ul>
</div><p>In related news, insider Soleil Boughton sold 268,932 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the sale, the insider now directly owns 169,803 shares in the company, valued at approximately $4,712,033.25. This represents a 61.30 % decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 36,460 shares of the business's stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $27.09, for a total value of $987,701.40. Following the transaction, the chief executive officer now owns 27,918 shares in the company, valued at approximately $756,298.62. This represents a 56.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 890,592 shares of company stock valued at $31,677,291 over the last 90 days. Corporate insiders own 17.71% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Soleil Boughton 于 1 月 6 日以交易方式出售了 268,932 股该股票。该股票的平均售价为 27.75 美元，总价值为 7,462,863.00 美元。出售完成后，该内部人士现在直接持有该公司 169,803 股，价值约为 4,712,033.25 美元。这代表其持股减少了 61.30%。该出售在提交给证券交易委员会的文件中披露，文件可通过 SEC 网站访问。此外，首席执行官 Andrew Dudum 于 1 月 16 日以交易方式出售了 36,460 股该公司的股票。该股票的平均售价为 27.09 美元，总价值为 987,701.40 美元。交易完成后，首席执行官现在持有该公司 27,918 股，价值约为 756,298.62 美元。这代表其持股减少了 56.63%。该出售的披露信息可以在此找到。内部人士在过去 90 天内出售了 890,592 股公司股票，价值 31,677,291 美元。公司内部人士持有该公司股票的 17.71%。</p>
</div><h2>Institutional Trading of Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>Hims</h2>
<p>&amp; Hers Health 的机构交易</p>
</div><p>Several large investors have recently bought and sold shares of HIMS. Crewe Advisors LLC purchased a new position in shares of Hims &amp; Hers Health in the fourth quarter valued at $28,000. Raleigh Capital Management Inc. lifted its holdings in Hims &amp; Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 1,100 shares in the last quarter. Blume Capital Management Inc. boosted its position in Hims &amp; Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Hims &amp; Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after acquiring an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC purchased a new stake in shares of Hims &amp; Hers Health during the fourth quarter worth about $38,000. Institutional investors and hedge funds own 63.52% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近购买和出售了 HIMS 的股票。Crewe Advisors LLC 在第四季度购买了 Hims
&amp; Hers Health 的新头寸，价值 28,000 美元。Raleigh Capital Management Inc. 在第四季度将其在 Hims
&amp; Hers Health 的持股增加了 1,100.0%。Raleigh Capital Management Inc. 现在拥有该公司 1,200 股股票，价值 29,000 美元，此前在上个季度又购买了 1,100 股。Blume Capital Management Inc. 在第四季度将其在 Hims
&amp; Hers Health 的持股增加了 100.0%。Blume Capital Management Inc. 现在拥有该公司 1,200 股股票，价值 29,000 美元，此前在上个季度又购买了 600 股。Smartleaf Asset Management LLC 在第四季度将其在 Hims
&amp; Hers Health 的持股增加了 4,415.6%。Smartleaf Asset Management LLC 现在拥有该公司 1,445 股股票，价值 36,000 美元，此前在上个季度又收购了 1,413 股。最后，Summit Securities Group LLC 在第四季度购买了 Hims
&amp; Hers Health 的新股份，价值约 38,000 美元。机构投资者和对冲基金持有该公司 63.52% 的股票。</p>
</div><h2>About Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>关于 Hims</h2>
<p>&amp; Hers Health</p>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health, Inc. 运营一个远程医疗咨询平台。它将消费者与医疗专业人员连接，使他们能够获得心理健康、性健康、皮肤病和初级护理的医疗服务。该公司成立于 2017 年，总部位于加利福尼亚州旧金山。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>Basic Materials Stocks Investing</li>
<li>Joby Aviation Stock: Virgin Atlantic Deal Signals Big Potential</li>
<li>What is the Hang Seng index?</li>
<li>Kohl’s Posts Another Kitchen Sink Quarter, But New CEO Has a Plan</li>
<li>What Are Some of the Best Large-Cap Stocks to Buy?</li>
<li>Southwest Airlines Could Triple From Here—Here's How</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Hims
&amp; Hers Health</li>
<li>基础材料股票投资</li>
<li>Joby Aviation 股票：维珍大西洋交易信号巨大潜力</li>
<li>恒生指数是什么？</li>
<li>Kohl’s 发布了另一个 “厨房水槽” 季度，但新 CEO 有计划</li>
<li>有哪些值得购买的大型股票？</li>
<li>西南航空可能会从这里三倍增长——这是方法</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=HIMS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Hims &amp; Hers Health 吗？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Hims &amp; Hers Health 并不在名单上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Hims &amp; Hers Health 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Hims & Hers Health（纽约证券交易所代码：HIMS）在美国银行被设定了新的 22.00 美元目标价